SB 525334是一种有效,选择性的转化生长因子β1受体 (ALK5) 抑制剂,IC50为 14.3 nM。
生物活性 | SB 525334 is a potent and selective transforming growth factor β1 receptor(ALK5)inhibitor with anIC50of 14.3 nM. |
IC50& Target | |
体外研究 (In Vitro) | SB525334 (1 μM; for 15 minutes before stimulating with 0.625 ng/ml of TGF-β1, assesses after 6 days) inhibits TGF-β1-mediated proliferation of familial idiopathic pulmonary arterial hypertension (iPAH) pulmonary artery smooth muscle cells (PASMCs) at an IC50of 295 nM[2].
Cell Proliferation Assay[2] Cell Line: | PASMC cells | Concentration: | 1 μM | Incubation Time: | Pre-incubated for 15 minutes (before stimulating with 0.625 ng/ml of TGF-β1), assessed after 6 days | Result: | Inhibited TGF-β1-mediated proliferation of familial iPAH PASMCs at an IC50of 295 nM. |
|
体内研究 (In Vivo) | SB525334 (3-30 mg/kg; p.o.; daily from days 17 to 35) significantly reverses pulmonary arterial pressure in a rat model of pulmonary arterial hypertension (PAH)[2].
Animal Model: | Adult male Sprague-Dawley rats (MCT rat model of pulmonary hypertension)[2] | Dosage: | 3, 30 mg/kg | Administration: | Oral administration; daily from days 17 to 35 | Result: | Reduced the proportion of fully muscularized vessels to 28% at 3 mg/kg and returned fully muscularized vessel distribution beyond that seen at day 17 and approaching the phenotype observed in saline-exposed controls at 30 mg/kg. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(291.19 mM;Need ultrasonic) 配制储备液 1 mM | 2.9119 mL | 14.5594 mL | 29.1189 mL | 5 mM | 0.5824 mL | 2.9119 mL | 5.8238 mL | 10 mM | 0.2912 mL | 1.4559 mL | 2.9119 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (7.28 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (7.28 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (7.28 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (7.28 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|